Half-year report · HY
3937.TEDINET S100WYYF
Period2025-04-01 → 2025-09-30
Filed2025-11-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥6.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥666m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥591m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥676m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥629m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥727m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥629m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥567m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥858m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥443m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥568m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥443m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥7.7bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥7.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥2.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.9bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥652m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥931m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥651m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥7m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥19m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥39m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥557m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥126m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥57m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥46.77 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.87 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.11 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.81 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 71.9% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.4% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥39m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥39m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥117m |
| Medicalreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥953m |
| Medicalreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥949m |
| Medicalreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥4m |
| Medicalreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥602m |
| Technology Consultingreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Technology Consultingreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Technology Consultingreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥35m |
| Technology Consultingreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥181m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥39m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥783m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥39m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥783m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥22m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥22m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥190m |
| Medicalreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥847m |
| Medicalreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥841m |
| Medicalreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| Medicalreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥542m |
| Technology Consultingreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.3bn |
| Technology Consultingreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.3bn |
| Technology Consultingreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥15m |
| Technology Consultingreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥240m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥22m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥22m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥781m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 514
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 3138502000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3138502000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 3138502000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 15194000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 6462000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 21657000 | JPY |
| Transactions with other segments | Prior1InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 21657000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -21657000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 2312815000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 847343000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 3160159000 | JPY |
| Net sales | Prior1InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3160159000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -21657000 | JPY |
| Net sales | Prior1InterimDuration | 3138502000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 239544000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 541784000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 781329000 | JPY |
| Operating income | Prior1InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 781329000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -189971000 | JPY |
| Operating income | Prior1InterimDuration | 591357000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 2026613000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 948740000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 2975354000 | JPY |
| Revenues from external customers | InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 2975354000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 2975354000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 35095000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 4331000 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 39426000 | JPY |
| Transactions with other segments | InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 39426000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -39426000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 2061709000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 953072000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 3014781000 | JPY |
| Net sales | InterimDuration_OtherReportableSegmentsMember | － | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3014781000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -39426000 | JPY |
| Net sales | InterimDuration | 2975354000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E32408-000TechnologyConsultingReportableSegmentMember | 180941000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E32408-000MedicalReportableSegmentMember | 602122000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 783063000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |